# GH Research Announces Publication of Phase 2a Postpartum Depression Results
Canonical URL: https://biopharmsignal.com/news/GHRS/gh-research-announces-publication-of-phase-2a-postpartum-depression-results
Ticker: GHRS
Company: GH Research
Source: GH Research
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.ghres.com
## Summary

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026).

## Article Body
DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026).
## Recent Company News
- 2026-06-25 13:46 EST — [GH Research Announces Publication of Phase 2a Postpartum Depression Results](https://biopharmsignal.com/news/GHRS/gh-research-announces-publication-of-phase-2a-postpartum-depression-results) — Source: GH Research
- 2026-06-25 13:46 EST — [GH Research Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GHRS/gh-research-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: GH Research
- 2026-06-25 13:46 EST — [GH Research Announces Global Pivotal Program Plans and Further Development Updates](https://biopharmsignal.com/news/GHRS/gh-research-announces-global-pivotal-program-plans-and-further-development-updates) — Source: GH Research
- 2026-06-25 13:46 EST — [GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/GHRS/gh-research-reports-second-quarter-2025-financial-results-and-provides-business-updates) — Source: GH Research
- 2026-06-25 13:46 EST — [GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress](https://biopharmsignal.com/news/GHRS/gh-research-announces-novel-therapies-symposium-presentation-and-posters-at-the-2025-ecnp-congress) — Source: GH Research
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)